Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
Authors:
Open Access
- 3 December 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Introduction: Acral melanoma (AM) has different biological characteristics from cutaneous melanoma. Although systemic therapeutic strategies for advanced AM resemble those for advanced cutaneous melanoma, the evidence of the clinical use of immune checkpoint inhibitors (ICIs) for AM is still inadequate. We aimed to systematically analyze the therapeutic effects and safety profile of ICI treatments in advanced AM. Methods: This systematic review was conducted in line with a previously registered protocol. Three electronic databases, conference abstracts, clinical trial registers, and reference lists of included articles were searched for eligible studies. The primary outcomes were therapeutic effects, and the secondary outcomes were the safety profiles. Results: This systematic review included six studies investigating anti-CTLA-4 immunotherapy, 12 studies investigating anti-PD-1 immunotherapy, one study investigating the combination therapy of anti-CTLA-4 and anti-PD-1, and one study investigating anti-PD-1 immunotherapy in combination with radiotherapy. In most studies investigating ipilimumab, the anti-CTLA-4 antibody, the objective response rate ranged from 11.4 to 25%, the median progression-free survival ranged from 2.1 to 6.7 months, and the median overall survival was more than 7.16 months. For studies discussing anti-PD-1 immunotherapy with nivolumab, pembrolizumab, or JS001, the objective response rate ranged from 14 to 42.9%, the median progression-free survival ranged from 3.2 to 9.2 months, and the median overall survival was more than 14 months. The combination therapy of anti-CTLA-4 and anti-PD-1 immunotherapy showed better efficacy with an objective response rate of 42.9% than single-agent therapy. The retrospective study investigating the combination therapy of anti-PD-1 immunotherapy and radiation showed no overall response. Few outcomes regarding safety were reported in the included studies. Conclusions: ICIs, especially anti-CTLA-4 monoclonal antibodies combined with anti-PD-1 antibodies, are effective systematic treatments in advanced AM. However, there remains a lack of high-level evidence to verify their efficacy and safety and support their clinical application.Keywords
This publication has 51 references indexed in Scilit:
- Radiotherapy and immune checkpoints inhibitors for advanced melanomaRadiotherapy and Oncology, 2016
- Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective ReviewThe Oncologist, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysisPigment Cell & Melanoma Research, 2014
- Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Melanoma (MEL)Annals of Oncology, 2012
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaNature Genetics, 2012
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or AmplificationJournal of Clinical Oncology, 2011
- Somatic Activation of KIT in Distinct Subtypes of MelanomaJournal of Clinical Oncology, 2006
- Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the TumorThe Journal of Immunology, 2005
- Differential Expression of Vascular Endothelial Growth Factor–A Isoforms at Different Stages of Melanoma ProgressionJournal of the American College of Surgeons, 2003